GSK has highlighted approval of Nucala in COPD as one of its top 2025 priorities, adding to its established medicines for the disease, including Trelegy (fluticasone furoate, umeclidinium ...

Ozempic/Wegovy is the first drug on HHS's 2025 list of Medicare price negotiations. As the leaders of the pharmaceutical industry boarded their planes to come home from the JP Morgan Healthcare ...